Cancer and common mental disorders in the community: Results of the Israel-World Mental Health Survey

 

 

Ora Nakash*; Anat Shemesh**; Maayan Nagar*; Itzhak Levav**

* School of Psychology, Interdisciplinary Center (IDC) Herzliya. Israel
** Ministry of Health, Jerusalem. Israel

This survey was funded by the Ministry of Health, the National Health Institute and the National Insurance Institute. It was carried out in conjunction with the World Health Organization/World Mental Health (WMH) Survey Initiative. We thank WMH Data Collection and Data Analysis Coordination Centers for their assistance. These activities were supported by the National Institute of Mental Health (R01 MH070884), the MacArthur Foundation, the Pfizer Foundation, the U.S. Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (FIRCA R03- TW006481), and the Pan American Health Organization.

Dirección para correspondencia

 

 

---

ABSTRACT

Background and Objectives: To study common mental disorders (CMD) and other mental health-related variables among community residents with active cancer, cancer survivors and cancer-free respondents.
Methods: Data were extracted from the Israeli component of the 28-country World Mental Health Survey. The sample included 165 respondents who reported ever having cancer and 2,282 cancer-free respondents, all aged 39 years and older. The WHO/Composite International Diagnostic Interview (CIDI) was used to determine the prevalence rate of CMD. Emotional distress (ED) was ascertained with the GHQ-12. Also, respondents were asked about sleep disturbances and mental health service utilization.
Results: Respondents with active cancer were more likely to endorse CMD in the past year than cancer-free respondents, 22.1% SE = 6.1 and 7.2% SE = 2.5, respectively (adjusted odds ratio = 2.6, 95% CI 1.2-5.6); to have higher ED scores, M = 27.1 SE = 1.3 and M = 19.8 SE = 0.3, respectively (Wald F = 16.7, p < 0.001); and higher prevalence rates of sleep disturbances, 64.7% SE = 6.5% and 31.5% SE = 4.6%, respectively (adjusted odds ratio = 2.1, 95% CI 1.1-3.9). Cancer survivors did not significantly differ from cancer-free respondents on the study variables. Despite the emotional toll, there were no differences in mental health service utilization among the three cancer groups.
Conclusions: Respondents with active cancer residing in the community show enhanced psychopathology. Study findings highlight a double need: to adequately assess mental health problems in persons with cancer and to bridge the treatment gap.

Key words: Epidemiology; Mental health; Oncology; Treatment gap; Israel.

---

 

Introduction

Cancer is a leading cause of death worldwide. In Israel it accounts for 26% of all deaths¹. Generally, the burden of cancer increases as the burden of infectious diseases decreases².

Importantly for mental health care, a significant proportion of community residents and clinic service users at all stages of the disease trajectory suffer from psychiatric morbidity, such as mood and anxiety disorders (common mental disorders - CMD)^3-7. A recent meta-analysis, including studies conducted in different countries, showed that one third of persons with cancer in acute care hospitals suffer from mental disorders⁸, while another meta-analytic study conducted in oncological, hematological and palliative-care units reported that about 25% and 10% had mood and anxiety disorders, respectively⁹. Additional studies found that 30%-50% of persons with cancer suffer from depression, and may benefit from early psychosocial intervention^4,5,10,11. Studies have found that incidence of psychiatric morbidity increases with rising levels of disability, advanced illness and pain¹², and that 30% to 50% of newly diagnosed patients with cancer have sleep disturbances^13,14.

Several factors have been noted to contribute to psychiatric morbidity and sleep disturbances, including the biological effects of the malignancy, side effects of chemotherapeutic drugs, grief about current and anticipated losses, and fear of death^11,15,16. Importantly, accurate diagnosis and appropriate treatment of mental health disorders in persons suffering from cancer can impact its course, days of hospital stays, treatment adherence and efficacy, and prognosis^6,17,18. The assessment of patients' mental health status shortly after the diagnosis of cancer is the best predictor for later adjustment disorder^19,20.

Despite the above-noted findings, the psychopathological status of persons with cancer often remains undetected and untreated^19,21-23. Approximately, only a third of severely distressed persons with cancer are recognized by their oncologists, and only 15%-50% of them are referred to specialized services^19,24. These failures may have detrimental effects on the course of illness and quality of life⁸, and coupled with objective barriers to care, e.g., limited availability and accessibility of mental health services, they contribute to the treatment gap^6,25. (Treatment gap is defined here by the difference between the true and treated prevalence of mental health disorders²⁶ among persons with cancer).

This treatment gap is frequent, even for people with cancer^3,6. For example, a community study conducted in the US showed that only 35% of cancer survivors who reported mental problems accessed specialized services²⁷. Another study, conducted among persons with cancer treated in a public hospital, showed that only 12% of those diagnosed with depression received antidepressant medications, and even a smaller percentage (5%) saw a mental health counselor²⁸. Muriel et al.²⁹ found that while oncologists estimated that over a third of their patients experience psychological distress needing intervention, only half of them reported making a referral to the mental health services.

Those studies were mostly originated in hospital and clinic settings. In contrast, only a few studies have examined the association between cancer and psychopathology in community samples³⁰. Also, only a few of them used structured diagnostic interviews, the gold standard in epidemiologic research. One study of this type³⁰, the US National Comorbidity Survey, found an association between cancer and major depression, specific phobias, agoraphobia and substance use. Another study³¹ found up to three times higher prevalence rates of depression and selected anxiety disorders among persons with cancer, compared with cancer-free respondents, controlling for socio-demographic variables and social support.

 

Objective

To study CMD, emotional distress, sleep disturbances and mental health service utilization among community residents with active cancer, and to compare their status with cancer survivors and cancer-free respondents.

Israel, that has a national health insurance system in which psychiatric care is freely available, constitutes a suitable context to examine the prevalence rates of both, mental disorders and service utilization, with regard to persons with cancer under favorable service conditions.

 

Methods

Survey design

This study was part of the Israel-based component of the World Mental Health Survey (WMHS) conducted in 28-countries in recent years³². The sample population was extracted from the National Population Register (NPR) and comprised non-institutionalized de jure residents aged 21 and older. The sample was designed to reflect the distribution in the general population of selected gender-age-ethnicity groups, and was weighted back to the total population to compensate for unequal selection probabilities resulting from disproportionate stratification, clustering effects and non-response³³. Face to face interviews at the respondents' homes were conducted from May 2003 to April 2004, in Arabic, Hebrew and Russian following the respondents' language preferences. Carefully trained and supervised professional interviewers administered the survey using laptop computer-assisted personal interview (CAPI) methods. Interviews took on average 60 minutes. The overall response rate was 73%, totaling 4,859 completed interviews, with no replacements.

A Human Subjects Committee approved the study.

This report refers to respondents aged above 39 years, as they were entering into the more frequent risk ages for cancer. Respondents that reported having cancer in their lifetime (n = 165; 6.7% of the total sample), being currently in active treatment (n = 55), in remission (n = 33), and cured (n = 77) were compared to those that reported never having cancer, henceforth, cancer-free respondents (n = 2,282). The respondents who reported being in remission and those reported to be cured were grouped as they did not show any significant differences on any of the key variables, henceforth labeled as cancer survivors (n = 110). Arab-Israeli respondents were not included in the following analysis because of their low numbers in this investigation (n = 13).

The survey questionnaire

It included:

Socio-demographic information, e.g., age, gender, years of education, marital status, and religiosity.

Diagnostic assessment. The WHO-Composite International Diagnostic Interview (CIDI)³² constituted the primary diagnostic instrument. CIDI is a structured interview which assesses ICD-10 and DSM-IV life-time- and 12 month-prevalence rates of selected psychiatric disorders. In the current study we focused on selected anxiety disorders (panic, generalized anxiety, agoraphobia without panic, and post-traumatic stress disorders), and mood disorders (major depressive disorder and dysthymia). Prevalence estimates of mental disorders were determined by whether respondents' past or current symptoms met lifetime and/or recent 12 month and diagnostic criteria for DSM-IV disorder. Screening items for each disorder were administered to each respondent. All participants who answered positively to the screening item were asked the diagnostic questions of the main questionnaire. Organic exclusion criteria were taken into account in determining DSM-IV diagnoses. Analysis for the current study examined recent 12 month diagnosis of CMD. This variable was diagnosed positive if respondents met criteria for any of the selected DSM-IV mood or anxiety disorders extracted from the CIDI³⁴. To establish that there were no significant variations in the severity of the diagnoses that were included we examined the differences in the Sheehan Disability Scale³⁵. Results showed that there were no significant differences in severity scores among them.

The CIDI interview schedule showed high test-retest reliability³⁶. WMH clinical reappraisal studies showed good CIDI-SCID agreement in DSM diagnoses and provide support for the construct validity of the interview³⁷. The WMH-CIDI was translated and back-translated from English to Hebrew, and all necessary adaptations were made. All three versions were reviewed by experts and pretested³³.

Chronic Physical Conditions. Respondents were asked whether a doctor or any other health professional ever told them they have a malignant tumor. Participants who replied yes to this screen question were further asked to indicate whether they are currently in "active treatment for the malignant tumour", "in remission" or "cured". Respondents were also asked whether a doctor or any other health professional ever told them they had heart disease, asthma, diabetes, kidney disease, neurodegenerative disease, chronic obstructive pulmonary disease, tuberculosis condition and whether they still had the condition in the past 12 months. Methodological research has shown that such checklists provide useful information about treated or currently undetected chronic conditions³⁸ and that they predict outpatient health care use, hospitalization and mortality³⁹. Self-report of chronic physical conditions shows moderate to high agreement with medical records data⁴⁰.

The General Health Questionnaire (GHQ-12)⁴¹. This 12-item scale measures emotional distress. Items were rated on a four point Likert scale and scores ranged from 12-48, where higher scores indicate increased emotional distress. All items have equal weight. Mean scores were calculated. GHQ-12 has been subject of many tests in many countries, including Israel⁴². In the current study, the GHQ-12 was used as a measure of demoralization for which it has documented adequate validity and reliability⁴³.

Sleep disturbances. Respondents were asked whether in the past 12 months they had a period of two weeks or more of one of the following disturbances: difficulty in falling or staying asleep, and early awakening. In this study, the disturbance was rated present if at least one of the three types of sleep disturbances was reported^33,36,37.

Mental health service utilization. Respondents were asked to indicate whether they had visited any one of a list of agents (health professionals: e.g., psychiatrist, psychologist, social worker, primary care physician, other doctors; religious counselors; and traditional and non-traditional healers) to talk about problems related to their mental health condition in the past 12 months. Due to statistical power constraints we grouped the services into those that are formal health services and other type of services^33,36,37.

Statistical analysis

All cancer sites were aggregated to increase statistical power. There were no significant differences in socio-demographic characteristics and medical and psychiatric morbidity between respondents who reported being "in remission" and those reported being "cured". Therefore, these groups were combined in the analysis and labeled cancer survivors.

Prevalence estimates were derived using standard survey procedures that accounted for sampling probabilities, as well as post-stratification adjustment to compensate for variation in survey non-response³³. Cross-tabulations were used to calculate bivariate odds ratios (ORs), 95% confidence intervals (95% CI) and p-values to assess the strength of the associations. Logistic and linear regression modeling accounted for the potential confounding effects of socio-demographic factors and other chronic health conditions in binary variables (e.g., psychiatric diagnosis) and continuous variables (e.g., GHQ-12 scores), respectively. The regression coefficients were transformed into adjusted odds ratios (AORs) and their 95% confidence intervals (95% CI) for ease of interpretation. We adjusted for confounding socio-demographic variables: age; gender; years of education; religiosity; and marital status. In addition, we adjusted for any self-reported chronic illness other than cancer. These variables were included in the final models if their association with cancer status and the mental health measures (i.e., CMD, GHQ-12, sleep disturbance) met a level of p < 0.1. All analyses were performed using SPSS Statistics version 18.0 for windows (SPSS Inc., 2009).

 

Results

Sample characteristics

Self-reported cancer sites included, breast (n = 52, 31.3%); intestine (n = 17, 10.2%); prostate (n = 21, 12.7%); skin (melanoma) (n = 17, 10.2%); uterus (n = 10, 6%); leukemia or lymphoma (n = 6, 3.6%); lung (n = 8, 4.8%); and other (n = 35, 21.1%). Cancer diagnosis was made on average, 9.4 SE = 0.7 years prior to the date of the survey, as follows: for respondents with active cancer, 6.3 years SE = 1.6, and for survivors, 10.6 years SE = 0.9.

Several demographic characteristics differed significantly by cancer statuses (Table 1). Respondents with active cancer were older, M = 66.6 SE = 1.7, and had less years of formal education, M = 11.0 SE = 0.7 than survivors, M = 61.4 SE = 1.2; and M = 13.1 SE = 0.4, respectively. They also differed with those who were cancer-free, M = 57.1 SE = 0.3; and M = 12.9 SE = 0.1, respectively.

 

 

Psychiatric morbidity

The 12 month-prevalence rates of CMD were statistically significantly higher for respondents with active cancer, 22.1% SE = 6.1%, compared with cancer survivors, 7.2% SE = 2.5%, and cancer-free respondents, 8.5%, SE = 0.6 χ² = 8.65, p < 0.05, AOR: 2.6 (95% CI 1.2-5.6). There were no significant differences in AOR for CMD between survivor- and cancer-free respondents (Table 2).

 

 

Emotional distress

Emotional distress showed significant differences in GHQ-12 scores between active cancer, M = 27.1 SE = 1.3, and cancer-free respondents, M = 19.8 SE = 0.3, Wald F = 16.7, p < 0.001 after controlling for socio-demographic variables and other chronic illnesses. There were no significant statistical differences in GHQ-12 scores between cancer survivors, M = 19.7 SE = 0.6, and cancer-free respondents, M = 19.8 SE = 0.3 (Table 3).

 

 

Sleep disturbances

Prevalence rates of sleep disturbance in the preceding 12 months were statistically significantly higher for respondents with active cancer, 64.7% SE = 6.5%, compared with survivors, 31.5% SE = 4.6%, and cancer-free respondents, 35.4% SE = 1%, χ² = 18.27, p < 0.001.

The adjusted odds ratio was 2.1 95% CI 1.1-3.9 for respondents who reported active cancer compared with those cancer-free. There were no significant statistical differences in the 12 month-rates of sleep disturbance between cancer survivors and the cancer-free respondents (Table 4).

 

 

Mental health service utilization

All respondents who had active cancer and cancer survivors reported seeking only formal health services for their mental health problems in the preceding 12 month and in lifetime, none reported seeking other services. No statistically significant differences were found in mental health service utilization in the preceding 12 months between active cancer respondents, n = 7, 12.5% SE = 4.5%, survivors, n = 11, 9.2% SE = 2.7%, and cancer-free respondents, n = 155, 7.1% SE = 0.6%, χ² = 2.82, p = 0.23. Similar proportions of active cancer, 24.4%, survivors, 34.8%, and cancer-free, 30.2%, respondents that had CMD had contacted professional services. Similarly, for the three groups that had no CMD, the service utilization rates did not differ, 9.2%, 7.3%, and 4.9%, respectively.

No differences were found in lifetime formal health service utilization by active cancer respondents, n = 14, 27.6% SE = 6.5%, cancer survivors, n = 23, 21.6% SE = 4.1%, and cancer-free respondents, n = 401, 17.6% SE = 0.8%, χ² = 2.68, p = 0.29. Similar results were obtained for emotional distress and sleep disturbances.

 

Discussion

This is the first epidemiological study on selected mental health problems and service utilization among community respondents with active cancer and cancer survivors in Israel. Our results showed that respondents who at the time of the study were undergoing treatment for cancer reported more mental health problems. More specifically, these respondents were two and a half times more likely to be diagnosed with CMD in the preceding 12 months, had higher emotional distress, and higher prevalence rates of sleep disturbance compared with cancer survivors and cancer-free respondents. Our findings confirmed the results of other community-based studies which showed that a significant proportion of persons with cancer have comorbid psychiatric disorders^3-5,8. Yet, the service utilization for mental problems did not differ from those who were cancer-free. Our findings also showed that cancer survivors did not differ from cancer-free respondent on the prevalence rates of the mental health problems we explored^44,45, a proxy measure of adjustment.

This study has important implications for the care of persons with cancer. It highlights the need for adequate mental health assessment of persons with cancer who can benefit from evidence-based treatment in primary care or in specialized services, thus improving the course and outcome of their disease and quality of life^6,8,17,18. In addition, it calls for the reduction of the treatment gap⁶, a public health problem that remains despite the existence of efficacious interventions for anxiety and depressive disorders, e.g., psychopharmacological⁴⁶ and psychotherapeutic (e.g., cognitive-behavioral therapy)⁴⁷ interventions. CMD may become part of a vicious cycle in which the cancer and the mental health problems affect each other in a negative cycle.

This study has several limitations. First, due to statistical power constraints analyses were performed on aggregate types of cancer and across genders and ethnic groups. These may have concealed differences. Second, no information was available on cancer stage, which may have an effect on the association with the mental health-related variables. Despite these limitations, we believe that the overall study contribution compensate its limitations.

 

References

1. Barchana M. Prevalence rates of cancer in Israel (Hebrew). 2011. http://www.health.gov.il/download/pages/probability_Feb_2011.pdf (accessed June 21 2011).         [ Links ]

2. World Health Organization. 2011. http://www.who.int/cancer/en/ (accessed 2 April 2011).         [ Links ]

3. Kadan Lottick NS, Vanderwerker LC, Block SD, Zhang B, Prigerson HG. Psychiatric disorders and mental health service use in patients with advanced cancer. Cancer 2005; 104: 2872-2881.         [ Links ]

4. Arden-Close E, Gidron Y, Moss-Morris R. Psychological distress and its correlates in ovarian cancer: A systematic review. Psycho-Oncol 2008; 17: 1061-1072.         [ Links ]

5. Meyerowitz BE, Oh S. Handbook of behavioral science and cancer: Psychosocial response to cancer diagnosis and treatment. Washington DC: American Psychological Association; 2009.         [ Links ]

6. Levav I. The treatment gap of depression in persons with cancer. Asian Pac J Cancer Prev 2010; 11: 117-119.         [ Links ]

7. Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer 2007; 110: 1665-1676.         [ Links ]

8. Singer S, Das-Munshi J, Brahler E. Prevalence of mental health conditions in cancer patients in acute care-a meta-analysis. Ann Oncol 2010; 21: 925-930.         [ Links ]

9. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. Lancet Oncol 2011; 12: 160-174.         [ Links ]

10. Vachon M. Psychosocial distress and coping after cancer treatment: How clinicians can assess distress and which interventions are appropriate-what we know and what we don't. Cancer Nurs 2006; 29: 26-31.         [ Links ]

11. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004; 2004: 57-71.         [ Links ]

12. Breitbart W. Identifying patients at risk for, and treatment of major psychiatric complications of cancer. Support Care Cancer 1995; 3: 45-60.         [ Links ]

13. Savard J, Morin CM. Insomnia in the context of cancer: A review of a neglected problem. J Clin Oncol 2001; 19: 895-908.         [ Links ]

14. Palesh OG, Roscoe JA, Mustian KM, Roth T, Savard J, Ancoli-Israel S, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol 2010; 28: 292-298.         [ Links ]

15. Carlson LE, Bultz BD. Efficacy and medical cost offset of psychosocial interventions in cancer care: Making the case for economic analyses. Psycho-Oncol 2004; 13: 837-849.         [ Links ]

16. Geinitz H, Zimmermann FB, Thamm R, Keller M, Busch R, Molls M. Fatigue in patients with adjuvant radiation therapy for breast cancer: Long-term follow-up. J Cancer Res Clin Oncol 2004; 130: 327-333.         [ Links ]

17. Reich M. Depression and cancer: Recent data on clinical issues, research challenges and treatment approaches. Curr Opin Oncol 2008; 20: 353-359.         [ Links ]

18. Pasquini M, Biondi M. Depression in cancer patients: A critical review. Clin Pract Epidemol Ment Health 2007; 3: 2.         [ Links ]

19. Sollner W, DeVries A, Steixner E, Lukas P, Sprinzl G, Rumpold G, et al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling? Br J Cancer 2001; 84: 179-185.         [ Links ]

20. Iscoe N, Williams JI, Szalai JP, Osoba D. Prediction of psychosocial distress in patients with cancer. In: Osoba D, editor. Effect of cancer on quality of life. London: CRC Press; 1991. p. 41-59.         [ Links ]

21. Passik SD, Dugan W, McDonald MV, Rosenfeld B, Theobald DE, Edgerton S. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998; 16: 1594-1600.         [ Links ]

22. Fallowfield L, Ratcliffe D, Jenkins V, Saul J. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer 2001; 84: 1011-1015.         [ Links ]

23. Fisch MJ, Titzer ML, Kristeller JL, Shen J, Loehrer PJ, Jung SH, et al. Assessment of quality of life in outpatients with advanced cancer: The accuracy of clinician estimations and the relevance of spiritual well-being-A Hoosier Oncology Group Study. J Clin Oncol 2003; 21: 2754-2759.         [ Links ]

24. Hardman A, Maguire P, Crowther D. The recognition of psychiatric morbidity on a medical oncology ward. J Psychosom Res 1989; 33: 235-239.         [ Links ]

25. Greenberg DB. Barriers to the treatment of depression in cancer patients. J Natl Cancer Inst Monogr 2004; (32): 127-135.         [ Links ]

26. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Org 2004; 82: 858-866.         [ Links ]

27. Hewitt M, Rowland JH. Mental health service use among adult cancer survivors: Analyses of the National Health Interview Survey. J Clin Oncol 2002; 20: 4581-4590.         [ Links ]

28. Ell K, Sanchez K, Vourlekis B, Lee PJ, Dwight-Johnson M, Lagomasino I, et al. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J Clin Oncol 2005; 23: 3052-3060.         [ Links ]

29. Muriel AC, Hwang VS, Kornblith A, Greer J, Greenberg DB, Temel J, et al. Management of psychosocial distress by oncologists. Psychiatr Serv 2009; 60: 1132-1134.         [ Links ]

30. Honda K, Goodwin RD. Cancer and mental disorders in a national community sample: Findings from the National Comorbidity Survey. Psychother Psychosom 2004; 73: 235-242.         [ Links ]

31. Rasic DT, Belik SL, Bolton JM, Chochinov HM, Sareen J. Cancer, mental disorders, suicidal ideation and attempts in a large community sample. Psycho-Oncol 2008; 17: 660-667.         [ Links ]

32. Kessler RC, Usten TB. The World Mental Health (WMH) survey initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004; 13: 93-121.         [ Links ]

33. Levinson D, Paltiel A, Nir M, Makovki T. The Israel national health survey: Issues and methods. Isr J Psychiatry Relat Sci 2007; 44: 85.         [ Links ]

34. Levinson D, Zilber N, Lerner Y, Grinshpoon A, Levav I. Prevalence of mood and anxiety disorders in the community: Results from the Israel National Health Survey. Isr J Psychiatry Relat Sci 2007; 44: 94-103.         [ Links ]

35. Sheehan DV. The anxiety disease. New York: Bantam Books; 1983.         [ Links ]

36. Kessler RC, Usten TB. The World Health Organization Composite International Diagnostic Interview. In: Kessler RC, Usten TB, editors. The WHO World Mental Health Surveys. New York: Cambridge University Press; 2006. p. 58-90.         [ Links ]

37. Haro JM, Arbabzadeh-Bouchez S, Brugha TS, De Girolamo G, Guyer ME, Jin R, et al. Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. In: Kessler RC, Usten TB, editors. The WHO World Mental Health Surveys. New York: Cambridge University Press; 2006. p. 114-127.         [ Links ]

38. Knight M, Stewart-Brown S, Fletcher L. Estimating health needs: The impact of a checklist of conditions and quality of life measurement on health information derived from community surveys. J Pub Health 2001; 23: 179-186.         [ Links ]

39. Fan VS, Au D, Heagerty P, Deyo RA, McDonell MB, Fihn SD. Validation of case-mix measures derived from self-reports of diagnoses and health. J Clin Epidemiol 2002; 55: 371-380.         [ Links ]

40. National Center for Health Statistics. Evaluation of National Health Interview Survey diagnostic reporting. Vital Health Stat 1994; 120: 1-116.         [ Links ]

41. Goldberg DP. Manual of the General Health Questionnaire. Windsor: NFER; 1978.         [ Links ]

42. Ponizovsky AM, Geraisy N, Shoshan E, Kremer I, Smetannikov E, Grinshpoon A. Emotional distress among first-time patients attending outpatient mental health clinics in Israel: An Arab-Jewish comparative study. Isr J Psychiatry Relat Sci 2007; 44: 62-70.         [ Links ]

43. Härter M, Woll S, Wunsch A, Bengel J, Reuter K. Screening for mental disorders in cancer, cardiovascular and musculoskeletal diseases. Soc Psychiatry Psychiatr Epidemiol 2006; 41: 56-62.         [ Links ]

44. Keating NL, Nørredam M, Landrum MB, Huskamp HA, Meara E. Physical and mental health status of older long term cancer survivors. J Am Geriatr Soc 2005; 53: 2145-2152.         [ Links ]

45. Earle CC, Neville BA, Fletcher R. Mental health service utilization among long-term cancer survivors. J Cancer Surviv 2007; 1: 156-160.         [ Links ]

46. Spijker J, Nolen W. An algorithm for the pharmacological treatment of depression. Acta Psychiatr Scand 2010; 121: 180-189.         [ Links ]

47. National Institute of Health and Clinical Excellence (NICE). Depression: Management of depression in primary and secondary care. NICE guidelines. 2004. http://www. nice.org.uk/Search.do?keywords=depression &newSearch =true&searchType=Guidance (accessed 2 April 2011).         [ Links ]

 

 

Correspondence:
Itzhak Levav, MD
Ministry of Health, 29 Rivka Street
Jerusalem, Israel
Tel: (972) 50 6 242079
E-mail: tuncho_levav@yahoo.com

Received: 29 May 2011
Revised: 9 January 2012
Accepted: 6 February 2012